Tuberculosis Transformative Science Group

The Tuberculosis Transformative Science Group (TB TSG) is responsible for development, implementation, and oversight of the ACTG research agenda related to the treatment and prevention of tuberculosis among patients with and without HIV co-infection. The primary objectives of the TB TSG are the evaluation and optimization of new and existing anti-TB drugs and drug combinations; development of shorter treatment regimens; treatment and prevention of MDR/XDR tuberculosis; and assessment of drugs or regimens for treatment of latent tuberculosis. Additional aims include: optimizing treatment of tuberculosis for patients receiving antiretroviral therapy (ART); evaluation of drug-drug interactions involving anti-TB agents and ART; improving TB diagnosis and evaluating new TB diagnostic tests and assays in the context of clinical trials; assessing biomarkers to predict and detect disease and monitor response to therapy; and developing novel clinical trial designs to enhance yield and efficiency.